Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC

This is the first clinical study of EP4 expression in lung cancer. There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year.